Should you buy these 3 beaten-up growth shares?

These three shares have been beaten-up recently, but are now offering interesting value propositions.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many investors would be pretty pleased with the fact that most of the top 20 ASX shares, including the big four banks and major miners, have enjoyed a great run over the past 12 months.

However, I feel that there isn't a lot of value left in many of the big name shares right now and that investors should start to look at other alternatives.

Fortunately, there are a number of shares that are currently offering pretty enticing risk-reward propositions, including:

Mantra Group Ltd (ASX: MTR)

The Mantra share price is trading at a 35% discount to its 52-week highs, largely on the back of fears of an oversupply of hotel rooms and the potential impact from Airbnb. The shares have been supported more recently on rumours of a takeover, although this has not progressed any further. Nonetheless, I wouldn't be surprised if Mantra is currently being looked at by possible suitors considering the growth of the tourism sector in Australia. Even without a takeover offer, I think Mantra currently offers an attractive value proposition considering the shares trade on around 16x earnings and a forecast grossed up dividend yield of around 6.5%.

Mayne Pharma Group Ltd (ASX: MYX)

The Mayne Pharma share price has fallen around 36% from its 52-week highs thanks to an ongoing U.S. investigation into allegations of price-fixing. Some investors have also been concerned about potential changes to the American health system under the new Trump administration. These are two important issues the generic drug company has to contend with, but I believe these short-term risks are now more than adequately reflected in the current valuation. At $1.35 per share, Mayne Pharma is trading on a historically low earnings multiple of less than 15x.

Catapult Group International Ltd (ASX: CAT)

The Catapult share price has fallen by more than 50% over the past nine months, despite the sport analytics company continuing to sign-up new sporting teams at an impressive rate. Unfortunately, the company's burgeoning top line growth hasn't been translated into any meaningful profitability yet and this has left some investors feeling frustrated. Nonetheless, Catapult is continuing to build scale and is developing a very fast-growing recurring revenue base that will be a crucial growth driver moving forward. As a result, I wouldn't write the company off just yet, although the shares are definitely only suitable for risk-tolerant investors.

Motley Fool contributor Christopher Georges owns shares of MANTRA GRP FPO and Mayne Pharma Group Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »